Alexandra Kropotova Sells Shares of SAB Biotherapeutics, Inc. $SABS

Written by Podchat · Published · Updated

Key Points

  • Alexandra Kropotova sold 988 shares of SAB Biotherapeutics, Inc. ($SABS).
  • $SABS last traded around $3.90.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Alexandra Kropotova, CHIEF MEDICAL OFFICER at SAB Biotherapeutics, Inc. ($SABS), sold 988 shares. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

SAB Biotherapeutics, Inc. Stock Up 2.9%

Shares of SAB Biotherapeutics, Inc. ($SABS) traded around $3.90 on Saturday, up 2.9% for the day.

Last price$3.90
Market cap$337.56M
P/E ratio16.13
Forward P/E-3.89
Beta0.53
52-week low$1.85
52-week high$5.15
50-day MA$3.75
200-day MA$3.81
Current ratio9.22
Quick ratio8.93
Debt-to-equity0.02

SAB Biotherapeutics, Inc. Earnings

EPS (ttm)$0.23
Revenue (ttm)—
Net margin0%
Return on equity-11.27%
Next earningsNov 12, 2026

Analysts Set New Price Targets

Average target$11.64
High target$16
Low target$6
Analysts covering11

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

ExchangeNasdaqCM
SectorHealthcare
IndustryBiotechnology
HeadquartersMiami Beach, FL
CEOMr. Samuel J. Reich
Employees86
Websitehttps://www.sab.bio

Get SAB Biotherapeutics, Inc. alerts

New 13F filings, insider trades, and analyst moves on $SABS, sent to your inbox. Free, and you can unsubscribe anytime.

Related Filing Alerts

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.